Pupaibool Jakrapun
Division of Infectious Diseases, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84112, USA.
Antibiotics (Basel). 2024 Dec 17;13(12):1223. doi: 10.3390/antibiotics13121223.
Rifampin is a crucial antibiotic in the management of prosthetic joint infections (PJI), particularly due to its effectiveness against staphylococcal bacteria and its ability to penetrate and disrupt biofilms. This review evaluates rifampin's role by examining its mechanism of action, clinical efficacy, and integration into treatment regimens based on recent evidence and guidelines. Rifampin's synergistic effects with other antibiotics, such as β-lactams and vancomycin, enhance bacterial eradication, and some evidence shows that it improves patient outcomes. However, evidence supporting its use is limited by the scarcity of robust human clinical trials, and challenges such as potential drug interactions and resistance development necessitate careful management. Ongoing research is needed to refine its use and address existing limitations in clinical practice.
利福平是治疗人工关节感染（PJI）的一种关键抗生素，特别是因为它对葡萄球菌具有有效性，并且能够穿透和破坏生物膜。本综述通过根据最新证据和指南研究其作用机制、临床疗效以及纳入治疗方案的情况，来评估利福平的作用。利福平与其他抗生素（如β-内酰胺类和万古霉素）的协同作用可增强细菌清除效果，一些证据表明它能改善患者预后。然而，支持其使用的证据因缺乏有力的人体临床试验而受到限制，并且诸如潜在药物相互作用和耐药性发展等挑战需要谨慎处理。需要进行持续研究以优化其使用并解决临床实践中现有的局限性。
